GSK aims at NASH target with $1bn-plus Arrowhead alliance
GlaxoSmithKline has joined the ranks of drugmakers trying to develop new drugs for non-alcoholic steatohepatitis (NASH) – a condition with no approved therapies and a lengthy list of failed drug candidates – via a deal with Arrowhead Pharmaceuticals. The bolt-on deal comes – which includes an upfront payment of $120 million and up to $910 […]